<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="580">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02023099</url>
  </required_header>
  <id_info>
    <org_study_id>M13-004</org_study_id>
    <nct_id>NCT02023099</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection</brief_title>
  <acronym>GIFT I</acronym>
  <official_title>A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Treatment-Naïve and Treatment-Experienced Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, double-blinded, multicenter study. The study will consist of 2
      substudies: Substudy 1 (SS1) will be double-blinded and enroll non-cirrhotic subjects and
      Substudy 2 (SS2) will be open label and enroll subjects with compensated cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy and safety data through 30 October 2014 are included in this presentation of the
      primary analysis. The primary analysis was conducted after all participants initially
      assigned to treatment with ABT-450/ritonavir/ABT- 267 (ABT-450/r/ABT-267; ABT-450 also known
      as paritaprevir; ABT-267 also known as ombitasvir) completed the post-treatment Week 12
      visit or prematurely discontinued the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Non-cirrhotic Treatment-naive Participants Who Are Eligible for Interferon (IFN)-Based Therapy and Who Have High Viral Load in the DB Active Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment</measure>
    <time_frame>12 weeks after the last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage noncirrhotic treatment-naïve participants who were eligible for IFN-based therapy and who had high viral load at baseline (HCV RNA ≥ 100,000 IU/mL) in the DB active treatment group with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [&lt; LLOQ]) 12 weeks after the last dose of active study drug (SVR12). Among noncirrhotic treatment-naïve participants who were eligible for IFN-based therapy and who had high viral load at baseline, superiority of Arm A to a clinically relevant threshold based on historical SVR rate with telaprevir plus pegylated interferon alpha/ribavirin (pegIFN/RBV) in treatment-naïve, non-cirrhotic patients with high viral load; the lower bound of 95% confidence interval (LCB) had to exceed 63% to achieve superiority. The 95% confidence interval was calculated using the normal approximation to the binomial distribution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in the Active Treatment Group With On-treatment Virologic Failure During Treatment</measure>
    <time_frame>up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>On-treatment virologic failure among all randomized non-cirrhotic participants who received at least one dose of DB ABT-450/r/ABT-267 and all enrolled participants with compensated cirrhosis who received at least one dose of OL ABT-450/r/ABT-267. On-treatment virologic failure is defined as the occurrence of at least one of the following:
confirmed HCV RNA ≥ LLOQ (defined as 2 consecutive HCV RNA measurements ≥ LLOQ) at any point during treatment after HCV RNA &lt; LLOQ (rebound), or
confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurements &gt; 1 log10 IU/mL above nadir) at any time point during treatment (rebound), or
HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks (≥ 36 days) of treatment (failure to suppress).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in the Active Treatment Group With Post-treatment Relapse</measure>
    <time_frame>within 12 weeks after last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Post-treatment relapse among all randomized non-cirrhotic participants who received at least one dose of DB ABT-450/r/ABT-267 and completed treatment, and all enrolled participants with compensated cirrhosis who received at least one dose of OL ABT-450/r/ABT-267 and completed treatment. Relapse was defined as confirmed HCV RNA ≥ LLOQ (defined as 2 consecutive HCV RNA measurements ≥ LLOQ) between the final treatment visit and 12 weeks after the last dose of study drugs among participants completing treatment and with HCV RNA &lt; LLOQ at the final treatment visit and at least one post-treatment HCV RNA value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in the Active Treatment Group With Sustained Virologic Response 12 Weeks Post-treatment Within Different Subpopulations</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sustained virologic response (plasma HCV RNA level &lt; LLOQ) 12 weeks after the last dose of study drug for all randomized non-cirrhotic participants who received at least one dose of DB ABT-450/r/ABT-267 in the following subpopulations:
noncirrhotic treatment-naïve participants with low viral load
noncirrhotic treatment-naïve participants who are ineligible for IFN-based therapy
noncirrhotic treatment-experienced participants who relapsed after prior IFN-based therapy
noncirrhotic treatment-experienced participants who were nonresponders to prior IFN-based therapy
noncirrhotic treatment-experienced participants who were intolerant to IFN-based therapy.
Sustained virologic response 12 weeks after the last dose of study drug for all enrolled participants with compensated cirrhosis who received at least one dose of open-label ABT-450/r/ABT-267.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">363</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Substudy 1, Arm A: DB 2-DAA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-blind (DB) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2 direct-acting antiviral agents [2-DAA]) once daily (QD) for 12 weeks in participants without cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DB placebo QD for 12 weeks followed by open-label (OL) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 2, Arm C: OL 2-DAA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OL 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants with compensated cirrhosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-450/r/ABT-267</intervention_name>
    <description>Tablet; ABT-450 coformulated with ritonavir and ABT-267</description>
    <arm_group_label>Substudy 1, Arm A: DB 2-DAA</arm_group_label>
    <arm_group_label>Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA</arm_group_label>
    <arm_group_label>Substudy 2, Arm C: OL 2-DAA</arm_group_label>
    <other_name>ABT-267 also known as ombitasvir</other_name>
    <other_name>ABT-450 also known as paritaprevir</other_name>
    <other_name>ritonavir also known as Norvir</other_name>
    <other_name>VIEKIRAX Combination Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HCV-infection prior to study enrollment

          -  Screening laboratory result indicating HCV subgenotype 1b infection

          -  Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening

          -  Voluntarily sign an informed consent

          -  Females must be practicing specific forms of birth control on study treatment, or be
             post-menopausal for more than 2 years or surgically sterile

        Exclusion Criteria:

          -  Co-infection of Hepatitis B Virus (HBV), HIV or any HCV genotype other than
             subgenotype 1b

          -  Prior therapy with direct acting antiviral agents for the treatment of HCV, including
             telaprevir, simeprevir and boceprevir

          -  Any cause of liver disease other than chronic HCV-infection, including but not
             limited to the following: hemochromatosis; alpha-1 antitrypsin deficiency; Wilson's
             disease; autoimmune hepatitis; alcoholic liver disease; drug-related liver disease;
             clinically significant laboratory abnormalities; uncontrolled clinically significant
             disease, disorder or medical illness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takuma Matsuda, MS</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie GK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121039</name>
      <address>
        <city>Asakura-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121033</name>
      <address>
        <city>Chuo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121024</name>
      <address>
        <city>Fukui-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120335</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121038</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121022</name>
      <address>
        <city>Gifu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123771</name>
      <address>
        <city>Gifu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123135</name>
      <address>
        <city>Hamamatsu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120360</name>
      <address>
        <city>Hiroshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121046</name>
      <address>
        <city>Hiroshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121043</name>
      <address>
        <city>Hitachi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121045</name>
      <address>
        <city>Ibaraki, Inashiki-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123138</name>
      <address>
        <city>Ikeda-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121030</name>
      <address>
        <city>Inzai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123767</name>
      <address>
        <city>Kagoshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121041</name>
      <address>
        <city>Kanazawa-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121032</name>
      <address>
        <city>Kawasaki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120336</name>
      <address>
        <city>Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120358</name>
      <address>
        <city>Kumamoto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123137</name>
      <address>
        <city>Kurume-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121559</name>
      <address>
        <city>Kyoto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120337</name>
      <address>
        <city>Maebashi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121028</name>
      <address>
        <city>Matsuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121560</name>
      <address>
        <city>Matsuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123770</name>
      <address>
        <city>Musashino-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121044</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123136</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121042</name>
      <address>
        <city>Obihiro-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123768</name>
      <address>
        <city>Ogaki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121018</name>
      <address>
        <city>Okayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121034</name>
      <address>
        <city>Okayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120359</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121026</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121050</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121049</name>
      <address>
        <city>Saga-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121037</name>
      <address>
        <city>Saitama, Iruma-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121047</name>
      <address>
        <city>Saitama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121048</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121035</name>
      <address>
        <city>Shimotsuke-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121040</name>
      <address>
        <city>Suita-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121027</name>
      <address>
        <city>Takamatsu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121021</name>
      <address>
        <city>Takasaki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121558</name>
      <address>
        <city>Tanabe-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121020</name>
      <address>
        <city>Tochigi, Shimotsuga-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120355</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120356</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120357</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121025</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123769</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121017</name>
      <address>
        <city>Toyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123215</name>
      <address>
        <city>Ube-city</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121023</name>
      <address>
        <city>Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121036</name>
      <address>
        <city>Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121031</name>
      <address>
        <city>Yufu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 27, 2015</lastchanged_date>
  <firstreceived_date>December 23, 2013</firstreceived_date>
  <firstreceived_results_date>October 27, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Genotype 1b</keyword>
  <keyword>Cirrhotic</keyword>
  <keyword>Treatment Experienced</keyword>
  <keyword>Treatment Naive</keyword>
  <keyword>Japanese</keyword>
  <keyword>ombitasvir</keyword>
  <keyword>paritaprevir</keyword>
  <keyword>ritonavir</keyword>
  <keyword>VIEKIRAX Combination Tablets</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Substudy 1, Arm A: DB 2-DAA</title>
          <description>Double-blind (DB) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2 direct-acting antiviral agents [2-DAA]) once daily (QD) for 12 weeks in participants without cirrhosis</description>
        </group>
        <group group_id="P2">
          <title>Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA</title>
          <description>DB placebo QD for 12 weeks followed by open-label (OL) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis</description>
        </group>
        <group group_id="P3">
          <title>Substudy 2, Arm C: OL 2-DAA</title>
          <description>OL 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants with compensated cirrhosis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="209">Completed double-blind study drugs</participants>
                <participants group_id="P2" count="106">Completed double-blind study drugs</participants>
                <participants group_id="P3" count="41">Completed open-label study drugs</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn Consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Virologic Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Substudy 1, Arm A: DB 2-DAA</title>
          <description>DB 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis</description>
        </group>
        <group group_id="B2">
          <title>Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA</title>
          <description>DB placebo QD for 12 weeks followed by OL 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis</description>
        </group>
        <group group_id="B3">
          <title>Substudy 2, Arm C: OL 2-DAA</title>
          <description>OL 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants with compensated cirrhosis</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="215"/>
                <measurement group_id="B2" value="106"/>
                <measurement group_id="B3" value="42"/>
                <measurement group_id="B4" value="363"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt; 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="129"/>
                <measurement group_id="B2" value="59"/>
                <measurement group_id="B3" value="21"/>
                <measurement group_id="B4" value="209"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>≥ 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="86"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="21"/>
                <measurement group_id="B4" value="154"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="135"/>
                <measurement group_id="B2" value="59"/>
                <measurement group_id="B3" value="22"/>
                <measurement group_id="B4" value="216"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="80"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="20"/>
                <measurement group_id="B4" value="147"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Non-cirrhotic Treatment-naive Participants Who Are Eligible for Interferon (IFN)-Based Therapy and Who Have High Viral Load in the DB Active Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment</title>
        <description>The percentage noncirrhotic treatment-naïve participants who were eligible for IFN-based therapy and who had high viral load at baseline (HCV RNA ≥ 100,000 IU/mL) in the DB active treatment group with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [&lt; LLOQ]) 12 weeks after the last dose of active study drug (SVR12). Among noncirrhotic treatment-naïve participants who were eligible for IFN-based therapy and who had high viral load at baseline, superiority of Arm A to a clinically relevant threshold based on historical SVR rate with telaprevir plus pegylated interferon alpha/ribavirin (pegIFN/RBV) in treatment-naïve, non-cirrhotic patients with high viral load; the lower bound of 95% confidence interval (LCB) had to exceed 63% to achieve superiority. The 95% confidence interval was calculated using the normal approximation to the binomial distribution.</description>
        <time_frame>12 weeks after the last dose of study drug</time_frame>
        <safety_issue>No</safety_issue>
        <population>Primary Efficacy Population: randomized non-cirrhotic treatment-naïve participants who are eligible for interferon-based therapy and who have high viral load and received at least one dose of double-blind ABT-450/r/ABT-267</population>
        <group_list>
          <group group_id="O1">
            <title>Substudy 1, Arm A: DB 2-DAA</title>
            <description>DB 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Non-cirrhotic Treatment-naive Participants Who Are Eligible for Interferon (IFN)-Based Therapy and Who Have High Viral Load in the DB Active Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment</title>
            <description>The percentage noncirrhotic treatment-naïve participants who were eligible for IFN-based therapy and who had high viral load at baseline (HCV RNA ≥ 100,000 IU/mL) in the DB active treatment group with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [&lt; LLOQ]) 12 weeks after the last dose of active study drug (SVR12). Among noncirrhotic treatment-naïve participants who were eligible for IFN-based therapy and who had high viral load at baseline, superiority of Arm A to a clinically relevant threshold based on historical SVR rate with telaprevir plus pegylated interferon alpha/ribavirin (pegIFN/RBV) in treatment-naïve, non-cirrhotic patients with high viral load; the lower bound of 95% confidence interval (LCB) had to exceed 63% to achieve superiority. The 95% confidence interval was calculated using the normal approximation to the binomial distribution.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="94.6" lower_limit="90.5" upper_limit="98.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in the Active Treatment Group With On-treatment Virologic Failure During Treatment</title>
        <description>On-treatment virologic failure among all randomized non-cirrhotic participants who received at least one dose of DB ABT-450/r/ABT-267 and all enrolled participants with compensated cirrhosis who received at least one dose of OL ABT-450/r/ABT-267. On-treatment virologic failure is defined as the occurrence of at least one of the following:
confirmed HCV RNA ≥ LLOQ (defined as 2 consecutive HCV RNA measurements ≥ LLOQ) at any point during treatment after HCV RNA &lt; LLOQ (rebound), or
confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurements &gt; 1 log10 IU/mL above nadir) at any time point during treatment (rebound), or
HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks (≥ 36 days) of treatment (failure to suppress).</description>
        <time_frame>up to 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>07/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in the Active Treatment Group With Post-treatment Relapse</title>
        <description>Post-treatment relapse among all randomized non-cirrhotic participants who received at least one dose of DB ABT-450/r/ABT-267 and completed treatment, and all enrolled participants with compensated cirrhosis who received at least one dose of OL ABT-450/r/ABT-267 and completed treatment. Relapse was defined as confirmed HCV RNA ≥ LLOQ (defined as 2 consecutive HCV RNA measurements ≥ LLOQ) between the final treatment visit and 12 weeks after the last dose of study drugs among participants completing treatment and with HCV RNA &lt; LLOQ at the final treatment visit and at least one post-treatment HCV RNA value.</description>
        <time_frame>within 12 weeks after last dose of study drug</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>07/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in the Active Treatment Group With Sustained Virologic Response 12 Weeks Post-treatment Within Different Subpopulations</title>
        <description>Sustained virologic response (plasma HCV RNA level &lt; LLOQ) 12 weeks after the last dose of study drug for all randomized non-cirrhotic participants who received at least one dose of DB ABT-450/r/ABT-267 in the following subpopulations:
noncirrhotic treatment-naïve participants with low viral load
noncirrhotic treatment-naïve participants who are ineligible for IFN-based therapy
noncirrhotic treatment-experienced participants who relapsed after prior IFN-based therapy
noncirrhotic treatment-experienced participants who were nonresponders to prior IFN-based therapy
noncirrhotic treatment-experienced participants who were intolerant to IFN-based therapy.
Sustained virologic response 12 weeks after the last dose of study drug for all enrolled participants with compensated cirrhosis who received at least one dose of open-label ABT-450/r/ABT-267.</description>
        <time_frame>12 weeks after last dose of study drug</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>07/2016</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious adverse events collected from initiation of study drug through 30 days post-study drug dosing; serious adverse events collected from signing of Informed Consent up to Post-treatment Week 48.</time_frame>
      <desc>For participants enrolled in Substudy 1, the duration of the study is up to 72 weeks long; for participants enrolled in Substudy 2, the duration of the study is 60 weeks long. Data presented for Arm B include events that occurred during placebo treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Substudy 1, Arm A: DB 2-DAA</title>
          <description>DB 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis</description>
        </group>
        <group group_id="E2">
          <title>Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA</title>
          <description>DB placebo QD for 12 weeks followed by OL 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis</description>
        </group>
        <group group_id="E3">
          <title>Substudy 2, Arm C: OL 2-DAA</title>
          <description>OL 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants with compensated cirrhosis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>MYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HEPATOCELLULAR CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>METASTASES TO BONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>RECTOSIGMOID CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ANURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYE DISCHARGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>GLOSSODYNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FACE OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>FEELING HOT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>LOCAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>THIRST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>TINEA PEDIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ALPHA-2 MACROGLOBULIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>APOLIPOPROTEIN A-I DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>BLOOD TRIGLYCERIDES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HAEMATOCRIT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTE MORPHOLOGY ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>RED BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PERIARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SPUTUM RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DERMATITIS ACNEIFORM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ECZEMA ASTEATOTIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PRURITUS GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Information</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
